Dr. Reddys Laboratories Ltd.

Dr. Reddy's is currently trading at Rs. 3788.00, up by 169.85 points or 4.69% from its previous closing of Rs. 3618.15 on the BSE.

The scrip opened at Rs. 3685.00 and has touched a high and low of Rs. 3853.85 and Rs. 3610.75 respectively. So far 61450 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3,853.85 on 13-Apr-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 3853.85 and Rs. 3200.00 respectively. The current market cap of the company is Rs. 62911.92 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.

Dr. Reddy's Laboratories has launched blood cancer drug Invista in India. The company's product is a formulation of Dasatinib that is bioequivalent to the innovator brand, Dr Reddy's Laboratories. Invista, which is available in strengths of 50, 70 and 100 mg tablets, is indicated for the treatment of primarily Chronic Myeloid Leukemia (CML). CML is a type of blood-cell cancer that begins in the bone marrow.

The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.